Skip to main content

bevyxxa

bevyxxa: developed by 1 company · 1 FDA decision.

bevyxxa evidence translation

What we can confirm

What it means

Source-backed records connect bevyxxa to PTLA; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could bevyxxa → PTLA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

prevention of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
PORTOLA PHARMACEUTICALS INC (PTLA)
prevention of venous thromboembolism (VTE) in adult patients…
Approved
FDA Decisions1 records
NDA208383Type 1 - New Molecular EntityPriorityOralCapsule

Frequently asked questions

Who is developing bevyxxa?

bevyxxa is being developed by PORTOLA PHARMACEUTICALS INC.

What is bevyxxa's latest FDA decision?

The most recent tracked FDA decision for bevyxxa is Approval, dated June 23, 2017.